These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

830 related articles for article (PubMed ID: 27793053)

  • 1. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
    Christofides A; Karantanos T; Bardhan K; Boussiotis VA
    Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
    Eich ML; Athar M; Ferguson JE; Varambally S
    Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting EZH2 in cancer therapy.
    Yamagishi M; Uchimaru K
    Curr Opin Oncol; 2017 Sep; 29(5):375-381. PubMed ID: 28665819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
    Li B; Chng WJ
    J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
    Xu B; Konze KD; Jin J; Wang GG
    Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.
    Italiano A
    Pharmacol Ther; 2016 Sep; 165():26-31. PubMed ID: 27179746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
    Gautam N; Kaur M; Kaur S
    J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
    Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The roles of EZH2 in cancer and its inhibitors.
    Liu Y; Yang Q
    Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Going beyond Polycomb: EZH2 functions in prostate cancer.
    Park SH; Fong KW; Mong E; Martin MC; Schiltz GE; Yu J
    Oncogene; 2021 Sep; 40(39):5788-5798. PubMed ID: 34349243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
    Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
    Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC1-C activates EZH2 expression and function in human cancer cells.
    Rajabi H; Hiraki M; Tagde A; Alam M; Bouillez A; Christensen CL; Samur M; Wong KK; Kufe D
    Sci Rep; 2017 Aug; 7(1):7481. PubMed ID: 28785086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
    Simon JA; Lange CA
    Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.
    Tsang DP; Cheng AS
    J Gastroenterol Hepatol; 2011 Jan; 26(1):19-27. PubMed ID: 21175789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers.
    Wan Z; Jiang H; Li L; Zhu S; Hou J; Yu Y
    Bioorg Med Chem; 2020 Apr; 28(7):115379. PubMed ID: 32098708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
    Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
    Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy?
    Jangal M; Lebeau B; Witcher M
    Expert Opin Ther Targets; 2019 Jul; 23(7):565-578. PubMed ID: 31177918
    [No Abstract]   [Full Text] [Related]  

  • 18. Polycomb Repressive Complex 2 in Oncology.
    Guo Y; Yu Y; Wang GG
    Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
    Sashida G; Iwama A
    Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 inhibitors: a patent review (2014-2016).
    Stazi G; Zwergel C; Mai A; Valente S
    Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.